Brief reports: Fluoxetine in panic disorder

Franklin R. Schneier; Michael R. Liebowitz; Sharon O. Davies; Janet Fairbanks; Eric Hollander; Raphael Campeas; Donald F. Klein

doi:10.1097/00004714-199004000-00007

Brief reports: Fluoxetine in panic disorder

Franklin R. Schneier, Michael R. Liebowitz, Sharon O. Davies, Janet Fairbanks, Eric Hollander, Raphael Campeas, Donald F. Klein

Research output: Contribution to journal › Article › peer-review

152 Scopus citations

Abstract

Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

Original language	English (US)
Pages (from-to)	119-121
Number of pages	3
Journal	Journal of Clinical Psychopharmacology
Volume	10
Issue number	2
DOIs	https://doi.org/10.1097/00004714-199004000-00007
State	Published - Apr 1990
Externally published	Yes

ASJC Scopus subject areas

Psychiatry and Mental health
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00004714-199004000-00007

Cite this

@article{83685a2de25249c1a391be2965791987,

title = "Brief reports: Fluoxetine in panic disorder",

abstract = "Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.",

author = "Schneier, {Franklin R.} and Liebowitz, {Michael R.} and Davies, {Sharon O.} and Janet Fairbanks and Eric Hollander and Raphael Campeas and Klein, {Donald F.}",

year = "1990",

month = apr,

doi = "10.1097/00004714-199004000-00007",

language = "English (US)",

volume = "10",

pages = "119--121",

journal = "Journal of Clinical Psychopharmacology",

issn = "0271-0749",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Brief reports

T2 - Fluoxetine in panic disorder

AU - Schneier, Franklin R.

AU - Liebowitz, Michael R.

AU - Davies, Sharon O.

AU - Fairbanks, Janet

AU - Hollander, Eric

AU - Campeas, Raphael

AU - Klein, Donald F.

PY - 1990/4

Y1 - 1990/4

N2 - Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

AB - Twenty-five patients with a primary DSM-III-R diagnosis of panic disorder with or without agoraphobia were treated openly with the serotonin uptake inhibitor fluoxetine for up to 12 months. For most patients, treatment was initiated at 5 mg/day to minimize adverse effects previously reported with initiation at higher doses. Nineteen (76%) experienced moderate to marked improvement in panic attacks. Four (16%) were unable to tolerate fluoxetine due to adverse effects. Initiating treatment of panic disorder with low doses of fluoxetine may increase its acceptability and permit more patients to benefit from fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=0025216663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025216663&partnerID=8YFLogxK

U2 - 10.1097/00004714-199004000-00007

DO - 10.1097/00004714-199004000-00007

M3 - Article

C2 - 2341585

AN - SCOPUS:0025216663

SN - 0271-0749

VL - 10

SP - 119

EP - 121

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

IS - 2

ER -

Brief reports: Fluoxetine in panic disorder

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this